Share Facebook
Crohn's Disease Forum » Books, Multimedia, Research & News » Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohnís disease.


01-30-2015, 04:34 PM   #1
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohnís disease.

Abstract Only:

Background:
Infliximab (IFX) and adalimumab (ADA) are effective in Crohnís disease (CD) for induction and maintenance therapy. However, high annual rate of discontinuation for loss of response or intolerance may lead to a switch to another anti-TNF agent. Patients with successive failure to IFX and ADA are becoming more frequent. The aim of this study was to assess the efficacy and the tolerance of re-treatment with IFX in CD patients who successively failed IFX and ADA.

Methods:
Sixty-one patients with CD who received and discontinued successively IFX and ADA, and who were re-exposed to IFX were identified in 4 French tertiary centers and retrospectively analyzed. Clinical data, follow-up and outcome were abstracted from medical records.

Results:
Median treatment duration after reintroduction was 16 months, and probability of remaining under IFX was 60% and 51% respectively at 12 and 24 months. Twenty-nine patients discontinued the second IFX treatment due to intolerance (13), primary non response (8), loss of response (7) or patientís wish (1). remission was achieved in 42% at week 6-8 after IFX re-induction, and was predictive of better long term response (p=0.006). In multivariate analysis, receiving co-immunosuppression in both first and second IFX treatment (p=0.04) and shorter interval between first and second IFX treatment (p=0.017) were independently associated with longer duration of second IFX treatment.

Conclusion:
For CD patients who successively failed IFX and ADA, re-introducing IFX is feasible and often clinically efficient, particularly in patients who received co-immunosuppression during both first and second IFX treatment.
When you click on the link below to the abstract you will see an option to open up the full article via a PDF. Although the PDF is crossed with Accepted Manuscript it is still easily readable:

http://ecco-jcc.oxfordjournals.org/c...cco-jcc.jju024
__________________
Mum of 2 kids with Crohn's.
Reply

Crohn's Disease Forum » Books, Multimedia, Research & News » Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohnís disease.
Thread Tools


All times are GMT -5. The time now is 12:42 AM.
Copyright 2006-2017 Crohnsforum.com